Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Deutsches Krebsforschungszentrum
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xf6 ffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Rechtes
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes
Deutsches Krebsforschungszentrum Stifting Des Offentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Offentlicen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Offentilchen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeffentichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeff
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffe
Deutsches Krebsforschungszentrum Stiftung Des xf6 ffentkuchen Rechts
Deutsches Krebsforschungszentrum stiftung Des xd6 ffen
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffetlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichenrechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Recht
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts_20100121

Deutsches Krebsforschungszentrum patents


Recent patent applications related to Deutsches Krebsforschungszentrum. Deutsches Krebsforschungszentrum is listed as an Agent/Assignee. Note: Deutsches Krebsforschungszentrum may have other listings under different names/spellings. We're not affiliated with Deutsches Krebsforschungszentrum, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Deutsches Krebsforschungszentrum-related inventors


Use of blocking-reagents for reducing unspecific t cell-activation

The present invention relates to a blocking-reagent for use in reducing unspecific T cell activation in T cell engaging therapies. The present invention further relates to pharmaceutical kit of parts and an in vitro method for evaluating unspecific T cell activation.... Deutsches Krebsforschungszentrum

Prediction of recurrence for bladder cancer by a protein signature in tissue samples

The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown... Deutsches Krebsforschungszentrum

Use of parvovirus for eliminating cancer stem cells (cscs)

Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.... Deutsches Krebsforschungszentrum

18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.... Deutsches Krebsforschungszentrum

Rna viruses expressing il-12 for immunovirotherapy

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the... Deutsches Krebsforschungszentrum

Norovirus antibodies

The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X1-F-Y-X2 (SEQ ID NO: 1), wherein X1 represents any amino acid, preferably Q or P, and wherein X2 represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates... Deutsches Krebsforschungszentrum

Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3

The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” S(AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for... Deutsches Krebsforschungszentrum

Hcbi, msbi, mssi and cmi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for the treatment and prevention of these diseases

Described are HCBI (Healthy Cattle Blood Isolate), MSBI (Multiple Sclerosis Brain Isolate), MSSI (Multiple Sclerosis Serum Isolate) and CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as... Deutsches Krebsforschungszentrum

Means and methods for diagnosing pancreatic cancer

The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the... Deutsches Krebsforschungszentrum

Receptors of rspo2 and rspo3

The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or... Deutsches Krebsforschungszentrum

Rna viruses for immunovirotherapy

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a... Deutsches Krebsforschungszentrum

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (MHC) class I or II. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding... Deutsches Krebsforschungszentrum

Methods for the prediction of a personalized esa-dose in the treatment of anemia

The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites... Deutsches Krebsforschungszentrum

Pancreatic cancer therapy and diagnosis

The present invention provides novel cancer therapeutics for treating pancreatic cancer, and novel diagnostic methods for detecting chronic pancreatitis and pancreatic cancer. The invention pertains to antagonists of dopamine receptors that inhibit the growth of pancreatic cancer cells. The invention in particular offers new therapy options based on the inhibition... Deutsches Krebsforschungszentrum

Binding molecules, especially antibodies, binding to l1cam (cd171)

The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises... Deutsches Krebsforschungszentrum

Mammalian dickkopf 3 (dkk3) as urinary marker for chronic kidney diseases

The present invention relates to dkk3 as a marker for diagnosing chronic kidney disease and assessing the risk of disease progression, as well as to related methods and uses. In particular, the present invention relates to method for diagnosing chronic kidney disease, comprising the steps of a) obtaining a urine... Deutsches Krebsforschungszentrum

S100p and hyaluronic acid as biomarkers for metastatic breast cancer

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of breast cancer in a patient. The method is based on the use of hyaluronic acid and S100P as combined biomarkers in the plasma of breast cancer patients. The new biomarkers of... Deutsches Krebsforschungszentrum

Inhibitors of thioredoxin-interacting protein (txnip) for therapy

Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (TXNIP) or (b) the expression of the gene encoding TXNIP for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan.... Deutsches Krebsforschungszentrum








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Deutsches Krebsforschungszentrum in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Deutsches Krebsforschungszentrum with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###